Morgan Stanley Leads $15B Anthropic Facility, But Valuation Stretched

What happened

Morgan Stanley is leading a $15 billion revolving credit facility expansion for Anthropic, a pre-IPO AI company, with Goldman Sachs, JPMorgan, and Citigroup also involved. This development fits squarely within the AI/IPO supercycle narrative that has driven Morgan Stanley's investment banking and capital markets revenue strength in 2025. The DeepValue master report already includes such AI-driven M&A and IPO pipelines as a key bull-case driver, assigning a 25% probability to a scenario where this cycle extends and MS's ROTCE sustains around 19-20%. However, the report maintains a POTENTIAL SELL rating with a base-case implied value of $180 vs. the current $191.90, arguing that the market has priced in sustained high returns and that 2025 earnings are near a cyclical peak. The Anthropic facility is a positive data point but does not alone change the assessment that risk-reward favors trimming at current levels.

Implication

The $15 billion facility led by Morgan Stanley signals its competitive strength in winning marquee AI mandates, which could support near-term investment banking revenues. However, this single transaction does not change the broader picture: Morgan Stanley trades at ~18-19x recent EPS and ~2.7x book, embedding expectations for sustained 20%+ ROTCE and ~30% wealth margins. The base case in the DeepValue report assumes capital-markets activity normalizes from 2025 peaks, with fair value around $180, implying modest downside from current levels. If the AI/IPO supercycle extends as the bull case suggests, the stock could reach $220, but that scenario has only a 25% probability and limited upside relative to downside risk. Therefore, investors should view the Anthropic news as confirmation of deal flow but not a reason to chase the stock; trimming or waiting for a pullback toward $165-$180 aligns with the report's risk-reward assessment.

Thesis delta

The Anthropic facility is consistent with the bull-case scenario of an extended AI/IPO cycle, but it does not alter the base-case probability distribution. The report's core thesis—that current valuation embeds cyclical peak earnings and offers poor risk-reward—remains unchanged. If anything, such high-profile mandates may reinforce consensus bullishness, increasing the risk of multiple compression if deal activity moderates.